MannKind stock has fallen sharply year to date, yet current valuation checks suggest the shares may already be close to their intrinsic value while market multiples still hint at some room on the upside. For investors, the picture is not a clear bargain or a clear overpricing, which makes the recent share performance especially important to understand.

• The stock is down about 27% year to date, which puts extra focus on whether the current price fairly reflects MannKind's long term cash flow potential.
• Future revenue growth and cash generation from its existing products and pipeline can support the equity story. However, uncertainty around the timing and scale of those cash flows remains a key risk for valuation.
• The broader checks give MannKind a mixed verdict overall, with a value score of 4 out of 6, which points to some measures looking cheap and others less so.

The stock's next move may depend on whether the current price already reflects MannKind's intrinsic value or still leaves a margin compared with the Discounted Cash Flow estimate and market multiples.

Broaden your watchlist by comparing MannKind with other stocks that valuation checks currently flag as potential mispricings using the 51 high quality undervalued stocks.

Does MannKind Look Fairly Valued on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what MannKind might be worth based on the cash it is expected to generate for shareholders. For MannKind, the latest twelve month free cash flow is a loss of about $24.1 million, so the model assumes that cash generation recovers over time rather than staying at current levels.

Using a 2 Stage Free Cash Flow to Equity approach, those projected cash flows translate into an estimated intrinsic value of about $4.53 per share. Compared with the current share price, this implies MannKind screens as roughly 9.6% undervalued on this DCF view. However, that outcome depends heavily on the path of future free cash flow turning positive and then growing steadily.

On this DCF view, MannKind stock looks roughly fairly valued with a mild tilt toward undervalued.

MannKind is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Is MannKind a Bargain on Sales?

The P/S ratio is often a useful way to look at MannKind because revenue is easier to track for a business that still reports losses on the bottom line.

MannKind currently trades on a P/S of about 3.3x. This is well below the biotech industry average of around 13.2x and also below the peer group average of roughly 14.5x. On the model used here, a fair P/S for MannKind is estimated at about 4.8x, which is higher than the current level.

The difference between the present 3.3x P/S and the 4.8x fair ratio indicates that the market is pricing MannKind at a discount to what its revenue profile and risk mix might typically command.

On this P/S view, MannKind stock appears undervalued compared with both industry norms and the modelled fair multiple.

The MannKind Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for MannKind pick up where the valuation puzzle leaves off by spelling out what future growth, margins and earnings would need to look like for the stock to be worth materially more or less than today’s price. Each Narrative links MannKind's potential catalysts and key risks to a specific valuation outcome so you can track over time which version of the story is closest to what actually happens.

One of the top community narratives on MannKind: 68% undervalued

"Another set of bullish analysts highlight the July 26 FDA action date for the Furoscix ReadyFlow Autoinjector as an underappreciated catalyst..."

Do you think there's more to the story for MannKind? Head over to our Community to see what others are saying!

The Bottom Line

MannKind looks close to its intrinsic value on the Discounted Cash Flow (DCF) view, with only a modest implied discount, while the sales multiple still points to an undervalued stock compared with peers. Together, the checks suggest the valuation is not a clear bargain, yet not obviously stretched either. What matters most from here is whether future cash flow and revenue progress line up with the expectations embedded in that DCF path. The key question for investors is whether today’s discount to peer P/S levels reflects opportunity or is the market’s way of pricing the uncertainty around MannKind’s execution and timing of cash generation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.